PCN96 A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)  by McLeod, EJ et al.
13th Euro Abstracts A269
therapy are well established and the combination regimens including a ﬂ uoropyrimi-
dine + oxaliplatin are the current standard of care. OBJECTIVES: To compare costs 
of XELOX with FOLFOX-4 as adjuvant treatment for stage III colon cancer under 
Brazilian private payer perspective. METHODS: Both regimens demonstrated to sig-
niﬁ cantly improve disease-free survival when compared to 5-FU/LV for adjuvant 
treatment of stage III colon cancer (MOSAIC and XELOXA trials). In the absence of 
head-to-head trials comparing both regimens, an indirect comparison using Butcher 
approach (Butcher 1997) was conducted. No difference was found regarding efﬁ cacy 
of regimens (XELOX vs. FOLFOX-4 in disease-free survival: HR 1.03, 95% CI 0.81, 
1.29); therefore, a cost-minimization analysis was used. a modiﬁ ed Delphi panel 
identiﬁ ed local practices to manage severe adverse events (SAEs) of each scheme. Only 
direct costs were considered for a patient with 1.7 m2. Drug prices were obtained from 
ofﬁ cial public sources (Kairos Magazine, April 2010) and administration costs from 
medical society physicians fee list (CBHPM2008, v.5). Time horizon was 6 months 
according to clinical recommendations: eight cycles for XELOX and 12 for FOLFOX-
4. Discounting was not applied. RESULTS: XELOX is less costly than FOLFOX-4 
($Brz49,862 vs. $Brz57,846). XELOX has higher acquisition costs which is offset by 
savings in medical resource utilization. Mean acquisition costs for XELOX were 
R$4185 higher than with FOLFOX-4, but costs to treat SAEs and administration costs 
were $Brz12,169 higher for FOLFOX-4. One-way sensitivity analysis conﬁ rmed the 
robustness of results. CONCLUSIONS: Findings suggest XELOX as a cost-saving 
therapy for the adjuvant setting under the private payer perspective in Brazil when 
compared to FOLFOX-4.
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OBJECTIVES: FOLFOX4 has been the chemotherapy of choice for patients with stage 
III colon cancer. Recently, the international NO16968 study reported results conﬁ rm-
ing the efﬁ cacy of XELOX in this setting, and evidence suggests that both regimens 
have at least equivalent efﬁ cacy. Therefore, medical and societal resource utilization 
are important factors for providers, patients, and payers. The objective of this analysis 
was to compare total costs required to treat an average aCC patient with either 
XELOX or FOLFOX4 in Switzerland. METHODS: In the absence of a direct com-
parison, detailed medical resource utilization (MRU) data collected for XELOX from 
study NO16,968 (aCC) and for FOLFOX4 from study NO16,966 (metastatic colorec-
tal cancer) were analyzed. The FOLFOX4 regimens are identical in both indications; 
therefore, MRU data from NO16,966 were considered valid proxies. In addition to 
direct MRU (chemotherapy, hospitalizations due to adverse events [AEs], ambulatory 
encounters, AE medication, and central venous access [CVA] placements), patient time 
and travel costs for hospitalizations, ambulatory encounters, and drug administration 
were estimated. Unit costs were derived from ofﬁ cial tariffs (Spezialitätenliste, Tarmed 
2010 for drug costs and physician services), ofﬁ cial statistics (hospital cost, mean 
hourly salary) and tax guidelines (travel costs). Total costs while on treatment (24 
weeks) for an average patient with aCC were compared. RESULTS: On average, 
XELOX saved CHF 11,471 per patient versus FOLFOX4. CHF 8883 resulted from 
savings in direct costs, mainly driven by savings in drug administration (CHF 9312) 
and CVA placements (CHF 1730). Savings in patient time and travel costs amounted 
to CHF 2588. CONCLUSIONS: XELOX appears to be cost-saving versus FOLFOX4 
in aCC from both a Swiss health-care system and the societal perspective, assuming 
equivalent efﬁ cacy for the two regimens. Considering the high incidence of colon 
cancer in Switzerland, substantial overall savings may be realized by routine use of 
XELOX in this indication.
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OBJECTIVES: In patients with chronic myeloid leukemia (CML), ﬁ rst-line treatment 
with imatinib therapy is beneﬁ cial. In cases of imatinib failure, second-generation 
tyrosine kinase inhibitors (TKIs) are recommended. Omacetaxine has a novel mode 
of action and acts independently of TKIs; thus, it may have therapeutic advantages 
for patients who have developed resistance to TKI therapy and have no available 
treatment options. The objective was to develop a health economic model to estimate 
the cost-effectiveness of omacetaxine in the treatment of CML. METHODS: A cost-
utility Markov model was developed to capture the progression of CML and treatment 
effects. The model was developed from the perspective of the French health-care 
system. Patients entered the model treated either with omacetaxine or standard care, 
in one of three phases: chronic, accelerated, or blast phase, having failed on imatinib 
therapy (through resistance or intolerance). Patients then moved to states of response, 
no response, or death. Survival estimates for nonresponding and responding patients 
were taken from studies 202 and 203. These were extrapolated using parametric curve 
ﬁ ts to estimate survival beyond the end of the trial. Resource use was based on the 
trial and from the expert opinion of a panel of French clinicians. Unit costs and utilities 
were elicited from the literature. One-way and probabilistic sensitivity analyses (PSA) 
were performed. RESULTS: The deterministic results demonstrated that treatment 
with omacetaxine is cost-effective at a threshold of c30,000. Sensitivity analysis 
showed that results were most sensitive to cost of omacetaxine, utility score, and 
survival beneﬁ t. PSA results showed that the model was sufﬁ ciently robust to param-
eter uncertainty. CONCLUSIONS: The analysis demonstrated that omacetaxine is 
cost-effective in the treatment of CML patients who are resistant to TKI therapy and 
have no available treatment options.
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OBJECTIVES: Paclitaxel albumin (P-A, Abraxane®) is nanoparticle albumin-bound 
paclitaxel formulated without use of irritant solvents that are responsible for many of 
the hypersensitivity and dose-limiting adverse events (AEs). Previous research has 
compared its cost-effectiveness to solvent-based paclitaxel (S-P) and docetaxel (DOC) 
in a cohort of patients with mixed treatment history. This study examined P-A’s cost-
effectiveness for pretreated MBC, the population speciﬁ ed in the European license. 
METHODS: A Markov model with progression-free, progressed, and mortality states 
was developed to estimate costs and outcomes over 5 years from a UK NHS perspec-
tive. Included from published sources were the costs at 2009 prices of drugs, admin-
istration, AEs, and supportive care. Published utility weights were applied to health 
states to estimate the impact of response, disease progression, and AEs on quality-
adjusted life-years (QALYs). Clinical data for pretreated patients receiving P-A 
260 mg/m2 3-weekly (q3w) and S-P 175 mg/m2 q3w were from Gradishar (2005). 
Using Bucher’s methods, an indirect comparison with Jones (2005) provided estimates 
of clinical parameters for DOC 100 mg/m2 q3w. Weibull extrapolations of survival 
data generated transition probabilities. RESULTS: Compared to S-P, P-A achieved an 
extra 0.164 QALYs, 0.263 life-years, and incurred additional costs of £4,137 per 
patient treated. This translated to an incremental cost-effectiveness ratio of £25,209/
QALY. P-A saved £697 when compared to DOC, with a marginal QALY gain of 
0.0037 and no life-expectancy divergence. Probabilistic sensitivity analysis versus 
DOC indicated a 61% likelihood of P-A satisfying a willingness-to-pay threshold of 
£30,000/QALY. Both comparisons were sensitive to drug costs and survival estimates. 
Accounting for potential drug wastage did not inﬂ uence interpretation of results from 
either comparison. CONCLUSIONS: The model found that P-A gave better outcomes 
than S-P or DOC and was cost-effective compared to both interventions. This 
depended upon greater efﬁ cacy than S-P and a more favorable safety proﬁ le than 
DOC.
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OBJECTIVES: To assess the cost-effectiveness of trastuzumab/anastrozole compared 
to lapatinib/letrozole, anastrazole, and letrozole for the treatment of HER2+/HR+ 
mBC patients in whom treatment with an aromatase inhibitor is suitable from a UK 
NHS perspective. METHODS: An area under the curve model based on the TAnDEM 
(trastuzumab/anastrozole vs. anastrozole) and EGF30008 (lapatinib/letrozole vs. letro-
zole) RCTs and the ﬁ ndings of a mixed treatment comparison (MTC) conducted on 
endocrine treatments in HR+ mBC was developed in Excel. a rank preserving structural 
failure time (RPSFT) model was utilized to account for the 70% crossover in TAnDEM. 
In the base-case, no attempt to account for the sizeable additional imbalance in 2nd line 
chemotherapy was made. The anastrozole PFS and RPSFT-adjusted OS curves from 
TAnDEM were utilized as a baseline from which to implement the required indirect 
comparisons under the assumption of an AI “class effect” (as suggested by expert clinical 
opinion and conﬁ rmed by the MTC). The present value of all costs and health outcomes 
attributable to each treatment option were calculated and the efﬁ ciency frontier deﬁ ned. 
Extensive deterministic and probabilistic sensitivity analyses were conducted. RESULTS: 
Anastrozole is dominated by letrozole. Lapatinib/letrozole is extendedly dominated by 
a combination of letrozole monotherapy and trastuzumab/anastrozole. Trastuzumab/
anastrozole produced the most QALYs of all regimens. Trastuzumab/anastrozole and 
letrozole deﬁ ne the efﬁ ciency frontier with a base-case ICER of £54,336/QALY. The 
use of the utility values derived from EGF30008 caused this ICER to fall to £44,497/
QALY. CONCLUSIONS: Lapatinib/letrozole is not a cost-effective use of ﬁ nite NHS 
resources at any cost-effectiveness threshold. As no attempt was made to account for 
the imbalance of 2nd line chemotherapy in TAnDEM (31% in anastrozole vs. 8% for 
trastuzumab/anastrozole) and relatively conservative utility values were used within 
the model the base-case ICER of trastuzumab/anastrozole vs. letrozole (£54,336/
QALY) should be regarded as conservative and the true ICER likely lies below 
£50,000/QALY gained.
